Thank you for submitting your manuscript for consideration by the EMBO Journal and my apologies for the delay in communicating our decision to you (I was travelling rather extensively over the last few weeks). Your study has now been seen by two referees whose comments are shown below. In addition, we have consulted with an external expert advisor in light of the comments from the reviewers.
As you will see from the reports, both referees highlight the importance and significance of the topic and findings reported, but at the same time referee #2 does raise concerns about the lack of information on the relative contribution from individual miRNAs and targets in the observed phenotype. However, both ref#1 and our external advisor appreciate the technical difficulties associated with achieving such data and find that the study does provide a significant advance to the field even without insight on individual miRNAs.
Given the referees' overall positive recommendations, I would therefore invite you to submit a revised version of the manuscript, addressing the comments made by both reviewers. In particular, I
would ask you to focus your efforts on the following points: -> If you were able to include some data on contributions from individual miRNAs, this would clearly strengthen the manuscript, but is not an absolute requirement from our side -> You should add further experiments to address the metabolic dysregulation responsible for metabolic maladaptation as requested by ref #2
-> You should also discuss the phenotypic discrepancy for the observed hypoglycemia, if possible supported by additional experimental data (ref #2) -> In addition, both refs raise a number of minor concerns that we would ask you to address before you submit a revised version of the manuscript.
I should add that it is EMBO Journal policy to allow only a single round of revision, and acceptance of your manuscript will therefore depend on the completeness of your responses in this revised version.
When preparing your letter of response to the referees' comments, please bear in mind that this will form part of the Review Process File, and will therefore be available online to the community. For more details on our Transparent Editorial Process, please visit our website: http://www.nature.com/emboj/about/process.html
We generally allow three months as standard revision time. As a matter of policy, competing manuscripts published during this period will not negatively impact on our assessment of the conceptual advance presented by your study. However, we request that you contact the editor as soon as possible upon publication of any related work, to discuss how to proceed. Should you foresee a problem in meeting this three-month deadline, please let us know in advance and we may be able to grant an extension.
Thank you for the opportunity to consider your work for publication. I look forward to your revision.
REFEREE REPORTS:
Referee #1 (Report):
In the manuscript "The miR-379/miR-410 cluster at the imprinted Dlk1-Dio3 domain controls neonatal metabolic adaptation", Stephane and colleagues report the characterization of mice carrying targeted deletion of the miR-379/miR-410 cluster. They show that newborn inheriting the targeted allele from the mother-but not those inheriting it from the father-display a marked increase in early postnatal lethality. They also show that in these mice the normal increase in hepatic glycogenolysis that follows birth is severely impaired and so is the increase in lipid oxydation induced by suckling. Based on these results, the authors hypothesize that the maternally inherited miR-379/miR-410 cluster modulates the gene expression program in the newborn livers that orchestrates the metabolic adaptations that characterize birth. To support this hypothesis, the authors have performed gene expression profiling experiments of control and mutant newborn livers. These experiments demonstrated changes in gene expression compatible with a profound and specific role of miR-379/410 in the neonatal liver at P0.
The manuscript is very well written, the experiments are clearly described, correctly interpreted, and include all the appropriate controls. The topic addressed is of substantial interest to the broad readership of Embo J.
The manuscript does not provide a clear mechanistic explanation of how miR-379/410 modulates the metabolic adaptations that follow birth, but the authors correctly argue that asking for one or two "key" targets that can explain such a complex phenotype would be naive.
There are two aspects that I would like to see addressed before this manuscript is accepted for
The EMBO Journal Peer Review Process File -EMBO-2013-87038 © EMBO 3 publication: a) the authors show that miR-379/410 is almost exclusively expressed in the brain of adult mice, while it is undetectable in the liver. Yet, the manuscript argues that this cluster acts, presumably directly, in the neonatal liver. For this to be true, it would be important to demonstrate that the members of this cluster are indeed expressed in the liver of newborn mice, perhaps transiently.
b) Although the authors show that deletion of miR-379/410 does not affect the expression of the other genes in the Dlk1-Dio3 domain, their analysis is limited to whole embryo, placenta, and brain. It would be important to confirm this finding in the liver of P0 animals, since that is the place where mis-regulation of neighbor genes would be more consequential. Given that the authors already have comprehensive gene expression analysis data ( fig. 5 ), addressing this point (perhaps in a supplementary figure) should be straightforward.
Referee #2 (Report):
Summary
In the present study, Labialle et al. describe the functional consequences of the genetic deletion of the miRNA379/410 cluster within the imprinted Dlk1-Dio3 locus in mice. In particular, the authors show that while deletion the miRNA cluster causes no profound growth abnormalities in these animals, a significant neonatal lethality could be observed upon miRNA cluster ablation. This phenotype was found to be correlated with alterations in postnatal glucose and ketone body homeostasis. Subsequent high throughput transcriptome analysis demonstrated that the deletion of the miRNA379/410 cluster had a substantial impact on the regulation of target gene pathways associated with energy homeostasis. The authors conclude that the miRNA379/410 cluster plays an important role in the metabolic adaptations at birth.
General comments
The metabolic adaptations during the transition from fetal to postnatal life clearly play a critical role for the individual's chances to survive. As most of the molecular mechanisms in metabolic control during this phase remain elusive, the current manuscript by Labialle et al. definitely addresses an interesting and important aspect in mammalian physiology. In this respect, particularly the discovery of the importance of a conserved miRNA cluster in this context describes an as-yet largely unexplored area of molecular metabolic research. However, despite the interesting and important topic, the manuscript in its current form remains at a rather descriptive level and yet fails to provide compelling mechanistic insights into the regulatory function of the miRNA379/410 cluster for metabolic adaptation. In particular, the following general questions require further experimental support: 1) Which particular miRNA and corresponding target pathway can explain the increased neonatal lethality in these animals, i.e. is it possible to mimic this phenotype by the deletion of individual miRNAs in this cluster? 2) Which metabolic dysregulation is responsible for the observed metabolic maladaptation, e.g. can you rescue the lethality phenotype by glucose injections? 3) How do you explain the appearance of mutant animals with mild and profound hypoglycemia, respectively, i.e. is there a molecular basis for this phenotypic separation at the genome-wide (transcriptomic) level? Experimental data to address these issues would clearly strengthen the case for publication. Additional minor comments are listed below.
Specific comments
Figure 3: Given the relative hyperglucagonemia in the mutant animals, please check the status of the insulin and glucagon signaling cascades in relevant tissues, e.g. by determining the phosphorylation status of Akt, GSK3, Foxo1, CREB etc. Is there a discrepancy between the mildly and severely hypoglycemic individuals? Point-by-point responses to the reviewer's comments
Reviewer 1
We are grateful for positive comments and helpful suggestions made by this reviewer to improve the quality of our manuscript.
a) The authors show that miR-379/410 is almost exclusively expressed in the brain of adult mice, while it is undetectable in the liver. Yet, the manuscript argues that this cluster acts, presumably directly, in the neonatal liver. For this to be true, it would be important to demonstrate that the members of this cluster are indeed expressed in the liver of newborn mice, perhaps transiently.
Although RT-qPCR experiments for some individual miRNAs from P0 newborn's liver were presented in Figure 2C , we agree with him/her that expression of miRNAs in the neonatal liver deserves more emphasis.
In the revised version, we now include:
1) The temporal expression of miR-379, miR-134, miR-410 and miR-376a from E18.5 to P28.
2) The perinatal expression of miR-379, miR-134, miR-410, miR-376a, miR-411, miR-380, miR-154, miR-377 in P1 mutant pups with mild and severe hypoglycemia. That miRNAs are barely detectable in the two classes of mutants renders very unlikely the trivial explanation according to which the incomplete penetrance of the neonatal lethality results from compensatory (or aberrant) reactivation on the normally-silent paternal allele. Those findings are important in the light of comments raised by reviewer 2 when he/she questioned the significance of the two classes of P1 mutants (see below his/her comment 3).
These miRNA expression data, included in the Figure We compared expression levels of Dlk1, Gtl2, Rian, Mirg and Dio3 transcripts in the P0 liver of WT, DMat and DPat pups. As reported for miRNAs, we also assayed temporal expression of these genes immediately after birth, from E19.5 to P1. Although some changes for Dlk1 and Dio3 mRNA levels were noticed in mutants as compared to WT, such modest mis-expression was, however, not seen in other independent qRT-PCR experiments (compare Figure E4 (panel B) and Figure E4 (panel C)). In addition, microarray analyses did not reveal any statistically significant misexpression of these two genes. We thus conclude that the targeted deletion of the miR-379/miR-410 cluster does not cause any important mis-expression of the flanking imprinted genes in the newborn's liver.
Those expression data, included in the Figure E4 (panels B-C), are mentioned on page 13.
Reviewer 2
Major comments:
1) Which particular miRNA and corresponding target pathway can explain the increased neonatal lethality in these animals, i.e. is it possible to mimic this phenotype by the deletion of individual miRNAs in this cluster?
To the best of our knowledge, there are no miRNA candidates encoded by the miR-379/miR-410 cluster whose loss-of-function may explain an increase in neonatal lethality. We noted, however, that the targeting of the miR-654/miR-376b locus -a genomic region embedded within the miR-379/miR-410 cluster -is not associated with embryonic lethality (Park et al (2012) Cell). Those observations remain, however, difficult to compare with ours. Indeed, the demonstration of a partially penetrant neonatal lethality phenotype requires a careful examination of a large number of litters, and from our understanding, these authors have not investigated further the immediate neonatal period.
The rationale of our study was to develop a genetic approach by considering the miR-379/miR-410 cluster as a single entity. While we fully understand the issue raised by this referee, we would like to remind him/her that ~ 77 miRNAs are generated from this huge cluster with some of them sharing sequence homologies, further complicating their functional analyses (i.e. redundancy and/or compensatory mechanisms cannot be excluded). Deciphering their functions by the deletion of individual miRNAs and identifying their corresponding target pathways will therefore require an enormous amount of time and resource (see also below her/his minor comment 5).
We are therefore not in the position to address this valuable comment which, in our opinion, remains beyond the scope of the present study.
2) Which metabolic dys-regulation is responsible for the observed metabolic maladaptation, e.g. can you rescue the lethality phenotype by glucose injections?
As requested by the reviewer, we asked whether glucose injections rescue the neonatal lethality phenotype. This was achieved through two independent experiments.
First, in the presence of the mother, all pups (cleaned and grouped in the nest) were systematically given a subcutaneous glucose injection (50 ml, 10%) shortly after delivery and then 4-6 hours later. This procedure was used to limit as much as possible the number of injected pups (blind experiments) while the mode of glucose injection was inspired by the recent work of Boj et al (2012) Cell. In order to avoid any bias due to the incomplete penetrance of the lethality, we only considered litters without any dead pups at the time of the first injection. Moreover, we did not include for analysis litters for which the mothers abandoned all the pups, very likely due to the invasiveness of the experimental procedures. As shown in Figure 3B , this experimental design increased, at least partly, neonatal survival as evidenced by the fact that 25/31 (80,6%) of glucoseinjected mutants survived birth transition (n=10 litters). In comparison, the perinatal survival rate of DMat without any glucose injections was 42 % (20/48), as observed from dead pups collected perinatally (Table 3) .
Second, glucose was also injected in pups kept separated from their mother and maintained in a moist, warm (32-35°C) atmosphere whereby maintaining glycaemia is mostly achieved by mobilization of hepatic glycogen stores. Again, we found that glucose injections extend the lifespan of DMat pups in such extremely challenging metabolic environment. Due to the inherent length of such experiment (>17H00), it was not feasible practically to monitor continuously the fate of injected pups, as shown in the original Figure 3C for a shorter time course. We therefore showed experimental values as histograms at two representative time points (10 and 17 hours postinjections).
Taken together, those observations point out that glucose dysregulation represents one of the major and earlier metabolic maladaptation linked to the neonatal lethality.
These experiments ( Figures 3B and 3C ) are described and discussed accordingly on pages 8 and 9.
3) How do you explain the appearance of mutant animals with mild and profound hypoglycemia, respectively, i.e. is there a molecular basis for this phenotypic separation at the genome-wide (transcriptomic) level? This reviewer points to a very important concern. First, we would like to stress that there is no obvious consensus (operational) definition of hypoglycemia in neonatal physiology, especially for mouse neonates. In the original version of the manuscript, we used 30 mg/dL as a critical glycemic threshold at P1 because only a very few WT displayed such low glucose levels (2/86; Figure E3 ). We are aware, however, about the arbitrary nature of such threshold. Indeed, glucose levels represent a snapshot of the metabolic status of an individual in a given litter at a given time. Blood glucose concentration is likely to change rapidly, especially in relation to maternal care, milk nutrition and other poorly understood physiological processes that occur simultaneously at birth transition. Based on the percentage of missing DMat neonates at weaning, it is nevertheless inferred that the lifespan of most DMat individuals with glycaemia ranging from 30-40 mg/dL is highly compromised. Indeed, assuming a morbid glycemic threshold at 40 mg/dL, then dead and hypoglycemic pups for WT and DMat genotypes account for 18% and 52,1 %, respectively (Figure entitled "for reviewers and editors only"_number 1). These values are consistent with % of neonatal death described in Table 3 . To clarify this issue, the corresponding paragraph was reworded in order to provide the reader with more information. A detailed analysis of dead and hypoglycemic pups (WT and DMat) in the immediate perinatal period is also given in Table 4 . We hope that it will help this reviewer and the readers to appreciate the dynamics of the metabolic status of neonates at birth transition. Note that during the revision process, a few additional litters have been included, hence some slight modifications in the corresponding Figures 3A and Figure E3 .
As recommended by this reviewer, mRNA profiling experiments were conducted at P1 when a fraction of DMat pups developed severe hypoglycemia. We thus compared the hepatic transcriptome of mutants with mild and profound hypoglycemia. Of importance, the impact of DmiR for the two classes of mutants was less detrimental at P1 as compared to what we previously reported at P0. It should be noted, however, that although transcriptomic defects in mutants with mild hypoglycemia were largely resolved, profoundly hypoglycemic mutants still exhibited alterations in gene expression. Thus, these analyses demonstrated phenotypic separation at the genome-wide (transcriptomic) level. Such separation based on transcriptomic profiles were not seen among mutants at P0. Not only do these findings reinforce our previous conclusions that the impact of miRNA deficiencies on hepatic transcriptome output are mostly seen during a very narrow temporal window after birth, they are also consistent with our assumption that mis-regulations above a certain threshold or for a more prolonged period may lead to severe hypoglycemia, and as a corollary, to fatal outcomes.
We are, nevertheless, aware that we still do not fully understand why some mutants seem to have recovered from the initial hypoglycemia. Answering this question is of primary interest but remains difficult to be addressed further. Any bias from genetic background is very unlikely since the partial penetrance of neonatal lethality is observed in rather purified C57BL/6J genetic background (N12). In addition, neonatal death is not seen in mutants having inherited the deletion paternally, further arguing against any confounding effects of the genetic background. As stated in the manuscript, neonatal lethality was also observed in crosses where the dams inherited the deletion maternally but also paternally, indicating that it is not strictly determined by the lack of expression of miR-379/miR-410 in the dams ("no grand-parental effect"). We can also exclude the trivial possibility that individuals with mild hypoglycemia re-expressed the miR-379/miR-410 cluster from the normally-silent paternal allele (see above our answer reviewer 1). Finally, we did not identify any obvious correlation between the neonatal lethality in a given litter and several parameters such as the number of DMat, the ratio of DMat vs WT pups, the length of gestation, the number of pregnancies of the dams.
We find reasonable to assume that DmiR first disrupts neonatal glucose homeostasis, particularly hepatic glycogen breakdown which is one of the very earliest adaptive event, hence the abnormal hypoglycaemia that developed as soon as a couple of hours after caesarean delivery. Together with defects in the timing of the activation of many metabolic genes, these primary metabolic defects may in turn decrease the ability of some lethargic mutants to compete efficiently for suckling, hence low milk intake and low ketone levels in mutants with severe hypoglycaemia. In this context, the individual history of each neonate within a given litter, perhaps their ability "to suckle in time", may allow some of them to recover despite their initial hypoglycaemia.
To satisfy her/his comments, and encouraged by specific recommendations made by EMBO J editors, we reshaped the discussion section in order to be more precise regarding the incomplete penetrance of the neonatal lethality phenotype.
This was done on pages 17-18.
Minor comments:
Figure 3: Given the relative hyperglucagonemia in the mutant animals, please check the status of the insulin and glucagon signaling cascades in relevant tissues, e.g. by determining the phosphorylation status of Akt, GSK3, Foxo1, CREB etc. Is there a discrepancy between the mildly and severely individuals?
We never claimed, as this reviewer seems to have interpreted, that mutant pups displayed hyperglucagonemia. His/her remark remains, nevertheless, valid in that we cannot rule out defective insulin and glucagon pathways even though hormonal levels in blood appeared unaltered. As suggested by this reviewer, we then measured the phosphorylation status of Akt, Fox01, Creb and GSK3b proteins using commercially-available antibodies (purchased from and used as recommended by Cell Signaling). The levels of phosphorylation were determined in the newborn's liver at P0 as well as at P1, including mildly and severely hypoglycemic individuals.
Representative western blots are shown in the file entitled "For reviewers and editors only_number 2". Despite many attempts, we failed to obtain any specific signal corresponding to P-Creb or P-Fox01 proteins while no clear differences between mildly and profoundly hypoglycemic mutants could be observed for P-Akt and P-GSK3b (panel A). Note that a-P-Creb antibodies revealed P-ATF-1, as expected from the Antibody Information Sheet provided by Cell Signalling.
Given its importance in the neonatal period, we then concentrated our efforts on the cAMP/Creb signaling pathway. First, we tried to measure hepatic cAMP concentrations (Cyclic AMP Direct Chemiluminescent EIA kit). Unfortunately, values were extremely low in the same range as the background (not shown). Second, we reasoned that phosphorylation could be transient and/or extremely labile. We then assayed P-Creb in P0 livers of WT pups after a subcutaneous injection of glucagon (35 ml at mg/ml). Again, and despite an obvious increase of blood glucose concentration, as expected, no specific P-Creb signals were revealed as early as 20 min post-injection (panel B). That P-Creb is easily detected in Forskolin-treated mouse cells (L929) excludes any trivial technical issues with our batch of antibodies (panel C).
We do not want to put too much emphasis on these inconclusive data. To satisfy this reviewer, we nevertheless included a sentence stating that we cannot rule out the possibility that insulin and glucagon signaling cascades are impaired in DMat mutants despite normal levels of pancreatic hormones in the blood.
This was done on page 11. In contrast to what the reviewer has interpreted, the decrease in ketone levels observed in profoundly hypoglycemic DMat pups at P1 is associated with a decrease of serum TG ( Figure 4C ). Although not reaching statistical significance, TG levels in the liver of profoundly hypoglycemic DMat Pups were also decreased as compared to WT or even mutants with mild hypoglycemia (Figures 4D-E) .
Low ketone levels are only observed in profoundly hypoglycemic DMat mutants with lower milk content in their stomach ( Figure 4J ). In rodents, newborns are devoid of adipose tissues and the mother's milk constitutes a prominent source of fatty acids (FA). Thus, reduced suckling activities in this subset of mutants, together with altered hepatic gene expression, could explain, at least partly, their lower ketone levels. Alternatively, but perhaps less probable, this decrease in ketone levels could also reflect an increase in their usage by peripheral tissues, i.e. a compensatory mechanism to counteract hypoglycemia.
Those considerations are now discussed on page 12.
As requested by this reviewer, FA oxidation measurements were performed on isolated hepatic cells. Newborn's livers at P0 were minced and hepatocytes were isolated after collagenase digestion. Isolated hepatocytes were then incubated with 14 C palmitate and complete fatty acid oxidation was determined by the release of 14 C CO 2. We did not detect any significant differences between DMat and WT pups. Note that FA oxidation was relatively low (average value in WT is 6311,88 nmol of 14 C CO 2 released per gram of proteins) and quite variable from one individual to another.
Those novel data are now included in Figure 4I and discussed accordingly on page 12. As we understand, this minor comment is somehow related to the previous major comment 1. There is no doubt that any rescue experiments by one target gene using a simplified in vitro cellular system will increase considerably our understanding of the causal link between lack of miRNA expression and defective metabolic adaptation. However, because nearly 2000 genes are mis-expressed in the newborns' liver and given that more than 10 000 mRNAs are potentially targeted by the miR-379/miR-410 cluster, addressing this issue is conceptually and technically challenging. To illustrate such complexity, one of the deleted miRNAs, namely miR-134, was predicted to target 2318 mRNAs. Based on a subset of randomly chosen in silico-predicted targets (n =158), it was shown that more than half of them could be qualified as a miRNA target as judged by luciferase reporter assay (Miranda et al (2006) Cell).
To the best of our knowledge, only a very few studies provide elegant and unequivocal evidence for the physiological importance of miRNA-mediated gene regulation in the mouse, i.e. by disrupting miRNA binding sites within the target mRNA (Dorsett et al Immunity (2008); Tend et al Immunity (2008) .
As discussed in our manuscript, and as also admitted by reviewer 1, it is very unlikely that misregulation of one target gene could account for such interlaced neonatal deficiencies. Moreover, those maladaptive neonatal metabolic responses imply also very likely complex genetic, nutritional and environmental interactions.
Thus, we felt unable to address this concern in a practical time-frame.
List of additional changes:
In addition to the above-mentioned text modifications introduced to satisfy the reviewer's comments, the manuscript was also slightly modified to follow more precisely the EMBO J guidelines. A few typos and minor mistakes that escaped our attention in the original version were also corrected. These changes do not alter the initial scientific content, nor its understanding.
The most significant changes are listed below: This sentence was deleted.
Figure 3H-I:
We modified slightly data from Figure 3H -I, notably E19.5 histograms, because some errors were present in the calculation made from raw data. These modifications do not change the results, nor their interpretations. Thank you for submitting your manuscript for consideration by the EMBO Journal and my apologies for the slight delay in our response to you (one of the referees had asked for additional time to re-assess your study).
Your revised manuscript has now been seen by both of the original referees and their comments are enclosed below. As you will see, while ref#1 finds that all criticisms have been addressed, ref#2 does raise a couple of points that would require additional experimental clarification (although I want to mention that this referee remains supportive of your work).
I fully understand the technical difficulties involved with addressing complex metabolic changes in newborn pups, but what ref#2 asks is in essence a more definite insight on the basis for the acid oxidation remains unchanged. The hypothesis that the ability "to suckle in time" may explain the changes in ketone body levels and/or the "rescue" of certain pups from hypoglycemia is interesting but speculative and may even point to non-hepatic (e.g. brain) side-effects of miRNA cluster deletion.
Overall, while the descriptive nature of the manuscript can be seen as a consequence of the general experimental approach (i.e. the simultaneous whole-body ablation of more than 70 miRNAs), the referee feels that some mechanistic details in metabolic pathway control would substantially strengthen the case for publication.
In this respect, a more detailed analysis of the glycogen storage/breakdown pathways in livers of wt and mutant animals in response to hormonal challenges (insulin, glucagon) may be useful in this direction and should be provided.
As a minor point, the authors state that "even though levels of neutral lipids and triglycerides were lower in severely hypoglycemic mutants, but without reaching statistical significance." By Definition, the absence of statistical significance also implies the absence of an effect, i.e. there is no decrease in TG levels if not statistically significant. This should be corrected.
2nd Revision -authors' response 02 July 2014
We are delighted to learn that both reviewers are, in general, satisfied with our revised manuscript and we thank them sincerely for their positive feedbacks and insightful comments upon this second round of reviewing.
Answers to the major comments of reviewer 2:
The hypothesis that the ability "to suckle in time" may explain the changes in ketone body levels and/or the "rescue" of certain pups from hypoglycemia is interesting but speculative and may even point to non-hepatic (e.g. brain) side-effects of miRNA cluster deletion.
As correctly pointed out by the reviewer, the constitutive deletion of the miRNA cluster renders the understanding of the metabolic deficiencies occurring in a subset of mutant pups even more complicated.
To satisfy his/her comment, we reshaped the paragraph as follows (page 18):
We are speculating that the ability "to suckle in time" may also allow some DMat neonates to recover and also perhaps to resolve their alterations in hepatic transcriptome. Given the constitutive deletion of the miRNA cluster, we cannot exclude the possibility that lack of miRNA expression in other tissues not investigated in this study, e.g. the newborn's brain, also impacts on this complex neonatal metabolic phenotype.
A more detailed analysis of the glycogen storage/breakdown pathways in livers of wt and mutant animals in response to hormonal challenges (insulin, glucagon) may be useful in this direction and should be provided.
We agree with the reviewer that "the metabolic characterization remains at a purely descriptive level" and that our work, at its current stage, lacks "convincing mechanistic insights into the metabolic adaptations". We are not sure that we understand correctly the rationale for analyzing glycogen metabolism in response to hormonal challenges. As mentioned already in our rebuttal letter, we are unable to detect P-Creb even in the livers of glucagon-injected WT newborn pups. We are not sure that we can easily address this concern within a reasonable time frame. Thus, we are reluctant to perform further time-consuming, expensive and risky experiments.
Answers to the minor comments of reviewer 2:
As a minor point, the authors state that "even though levels of neutral lipids and triglycerides were lower in severely hypoglycemic mutants, but without reaching statistical significance." By definition, the absence of statistical significance also implies the absence of an effect, i.e. there is no decrease in TG levels if not statistically significant. This should be corrected.
This is a valid point. The incriminated sentence was deleted (page 12).
